Protara Therapeutics (TARA) announced the appointment of William “Bill” Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. Conkling most recently served as president and CEO of Rafael Holdings, a holding company with interests in clinical and early-stage pharmaceutical companies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics initiated with a Buy at JonesResearch
- Protara Therapeutics Reports Q1 2025 Financial Results
- Protara Therapeutics: Buy Rating Affirmed Amid Promising Clinical Data and Strong Financial Position
- Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile
- Protara Therapeutics appoints Nicacio as CMO, Williams as CPO